Source:Cancer Treatment Reviews
Author(s): Tony S.K. Mok, Lucio Crino, Enriqueta Felip, Ravi Salgia, Tommaso DePas, Daniel S.W. Tan, Laura Q.M. Chow
The discovery of anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC) in 2007 led to the development and subsequent approval of the ALK inhibitor crizotinib in 2011. However, despite its clinical efficacy, resistance to crizotinib invariably develops. There is now a next generation of ALK inhibitors, including two that have been approved—ceritinib and alectinib—and others that are in development—brigatinib, lorlatinib and X-396. Ceritinib and the other next-generation ALK inhibitors are more potent than crizotinib and can overcome tumor cell resistance mechanisms. Ceritinib gained US Food and Drug Administration approval in 2014 following accelerated review for the treatment of patients with ALK-positive (ALK+) metastatic NSCLC who have progressed on or are intolerant to crizotinib.In pre-clinical studies, itdemonstrated more potent inhibition of ALK than crizotinib in enzymatic assays, more durable responses in xenograft models andthe ability to potently overcome crizotinib resistance mutations in vitro (including the gatekeeper mutation). There is also evidence for crizotinib penetration across the blood-brain barrier. In clinical trials, ceritinib has demonstrated durable responses and progression-free survival in ALK-inhibitor–pre-treated and –naïve NSCLC patients, including high overall and intracranial response rates in those with central nervous system metastases. Selective gastrointestinal toxicity of ceritinib, such as diarrhea, nausea and vomiting is generally manageable with prophylactic medication and prompt dose reduction or interruption. Future progress in treating ALK+ NSCLC will focus on determining the optimal sequencing of therapies and strategies to overcome acquired resistance, an ongoing challenge in treating ALK-mutation–driven tumors.
http://ift.tt/2nCshj6
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου